IRD is trading about 6% up in pre-market near $4.28, rebounding from a recent pullback as investors react to Phase 3 FDA alignment for OPGx-LCA5 and bullish analyst commentary.
- Shares are currently consolidating recent gains as traders digest the clinical news alongside broader risk-off sentiment in the futures market.
- The stock’s ongoing move is supported by high optimism regarding its clinical pipeline and positive feedback from market analysts.